Drugs / RP-A601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05885412 | Aug 2023 → Sep 2028 expected | familial cardiomyopathy | Rocket Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-A601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05885412 ↗ |
| Route | Intravenous | “single dose intravenous infusion of RP-A601” NCT05885412 ↗ |